# Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/rivaroxaban-versus-warfarin-in-patients-with-nonvalvular-atrial-fibrillation-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Craig I Coleman,Reinhold Kreutz,Nitesh Sood,Thomas J. Bunz,Daniel Eriksson,Anna‐Katharina Meinecke,William L. Baker |
| Citations | 123 |
| DOI | 10.1016/j.amjmed.2019.04.013 |
| Fields | Medicine,Pharmacology, Toxicology and Pharmaceutics |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2970895804 |
| PMID | 31054829 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Daniel Eriksson](https://scholariq.org/researchers/daniel-eriksson/)

## Paper journal

- [The American Journal of Medicine](https://scholariq.org/journals/the-american-journal-of-medicine/)

## Paper primary topic

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Paper topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Acute Kidney Injury Research](https://scholariq.org/topics/acute-kidney-injury-research/)
- [Pharmacovigilance and Adverse Drug Reactions](https://scholariq.org/topics/pharmacovigilance-and-adverse-drug-reactions/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.